# UK Brucellosis Market > UK Brucellosis Market Research Report: Size, Share, Trend Analysis By species (Brucella suis, B. abortus, B. melitensis), Regions - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.02% - **2024:** $ 24.66 Million - **2025:** $ 26.39 Million - **2035:** $ 52 Million - **Key Players:** Zoetis Inc (US), Merck & Co Inc (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR), Phibro Animal Health Corporation (US) **Report ID:** MRFR/LS/51827-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-brucellosis-market-53588 --- ## Market Summary ## **UK Brucellosis Market Overview** As per MRFR analysis, the UK Brucellosis Market Size was estimated at 12.81 (USD Million) in 2023.The UK Brucellosis Market is expected to grow from 13.95(USD Million) in 2024 to 62.5 (USD Million) by 2035. The UK Brucellosis Market CAGR (growth rate) is expected to be around 14.607% during the forecast period (2025 - 2035). **Key UK Brucellosis Market Trends Highlighted** Currently, a number of important market trends are influencing the UK brucellosis industry. The growing concerns about food safety and animal health, which have prompted more monitoring and brucellosis immunization programs for livestock, are among the major factors propelling the market. In order to preserve the integrity of the agricultural industry, the UK government aggressively supports biosecurity measures that stop the introduction and spread of brucellosis in sheep and cattle. In order to guarantee a coordinated response to outbreaks and present a unified front against the disease, cooperation between veterinary authorities, farmers, and agricultural groups is also growing increasingly frequent. Additionally, there are noteworthy prospects in the UK brucellosis market. There is an opportunity to improve illness identification and treatment by focusing on research and development for efficient vaccinations and diagnostics. Additionally, farmers are encouraged to use healthier livestock management practices by the growing interest in sustainable farming methods, which can help lower the prevalence of brucellosis. Recent trends show that the public is becoming more aware of zoonotic illnesses, which has led to increased brucellosis education initiatives. Governmental organizations that describe the dangers of eating unpasteurized dairy products provide support to this. There is a drive to certify brucellosis-free products in order to bring value to the market, as consumers' preferences for openness in food supply grow. All things considered, the UK brucellosis market is changing as a result of continuous initiatives to reduce hazards and improve animal health, setting up the industry for expansion and improved human and animal health outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK Brucellosis Market Drivers** **Rising Awareness and Research on Zoonotic Diseases** The increasing focus on zoonotic diseases like Brucellosis among healthcare professionals and researchers is driving growth in the UK [Brucellosis Market](../../../reports/brucellosis-market-5159). According to the UK's Zoonoses Action Plan initiated by the Department of Environment, Food & Rural Affairs, there has been a marked increase in funding for Research and Development (R&D) on infectious diseases that affect both animals and humans. In recent years, there has been a 25% increase in government-funded research initiatives aimed at battling zoonotic infections. Notable organizations like Public Health England have also emphasized the importance of understanding zoonotic diseases, consequently fostering a more profound awareness and prompting academic institutions to invest in comprehensive Brucellosis studies. This heightened focus ensures that there is consistent progress in diagnostics and treatment options, ultimately propelling the UK Brucellosis Market towards expansion. **Government Initiatives and Support for Animal Health** The UK government's stringent regulations on livestock health and insurances against infectious diseases are significant drivers in the UK Brucellosis Market. In collaboration with organizations such as the Animal and Plant Health Agency, the UK government has implemented various measures, including vaccination programs and strict testing protocols that have led to a sharp decline in Brucellosis cases among livestock by approximately 40% over the past decade. These government initiatives not only help control the disease but also support farmers and herd owners financially, further encouraging them to seek health solutions. This creates a favorable environment for market players involved in Brucellosis diagnostics and treatments. **Growing Demand for Effective Diagnostic Solutions** As awareness increases regarding the complexities surrounding Brucellosis, there is a heightened demand for effective diagnostic solutions within the UK Brucellosis Market. The Veterinary Medicines Directorate, a part of the UK government, reported a 30% rise in requests for Brucellosis diagnostic tests over the last five years, highlighting the pressing need for rapid and accurate testing methods. This increase is also influenced by the requirements set by various agricultural bodies, stressing the importance of early detection for herd management and public health safety. Key players in the diagnostic field are have noted an upsurge in investment towards the development of innovative solutions, thereby propelling the market forward. **UK Brucellosis Market Segment Insights** **Brucellosis Market species Insights** The UK Brucellosis Market focuses on various species contributing to the overall landscape, primarily encompassing Brucella suis, B. abortus, and B. melitensis, which are critical in the study and management of this infectious disease in animals and humans. Brucella suis is significant as it affects swine populations, making it essential for livestock industries to manage this zoonotic disease effectively, as it poses a risk for transmission to humans. B. abortus, typically associated with cattle, dominates the market due to its impact on agricultural operations, where outbreaks can lead to significant financial losses and regulatory challenges. The importance of this species cannot be overstated; in the UK, cattle are cornerstone assets in the agricultural ecosystem, and controlling B. abortus is paramount in ensuring both health and economic stability in the sector. Conversely, B. melitensis, primarily linked with goats and sheep, presents its own challenges due to its capability to cause severe human infections, thus affecting public health initiatives. The vigilance and resource allocation towards monitoring and controlling these species are reflected in the demand for diagnostic tools and vaccines. The UK government has implemented various strategies to control brucellosis in livestock, including vaccination programs and surveillance initiatives, ensuring that the agricultural community remains proactive against potential outbreaks. The market's segmentation reveals that each species possesses unique epidemiological characteristics that require tailored control measures, therefore shaping the trajectory of the UK Brucellosis Market and providing ample opportunities for growth in research and veterinary services aimed at combating this public health threat. In summary, the intricate dynamics surrounding these brucellosis-causing species underscore the need for continued investment in surveillance, research, and veterinary care to mitigate the risks associated with B. suis, B. abortus, and B. melitensis, ultimately fostering a healthier livestock population and protecting public health within the UK. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK Brucellosis Market Key Players and Competitive Insights** The competitive landscape of the UK Brucellosis Market is characterized by a growing emphasis on animal health, biosecurity measures, and innovative pharmaceutical solutions tailored to address the challenges posed by Brucellosis. This zoonotic disease affects livestock, primarily cattle, goats, and sheep, leading to economic losses for farmers and posing public health risks. The market consists of various players, including global pharmaceutical companies and specialized veterinary service providers, each vying to establish a foothold through strategic partnerships, research and development initiatives, and marketing efforts aimed at educating stakeholders about disease prevention and management. As the awareness of Brucellosis's implications on livestock and public health intensifies, the competition among market players is expected to lead to the introduction of advanced diagnostic tools and vaccines, as well as more effective treatment options, enhancing overall market growth. Elanco holds a prominent position in the UK Brucellosis Market, leveraging its extensive portfolio of animal health products and solutions aimed at preventing and controlling infectious diseases. The company is recognized for its commitment to research and development, which enables Elanco to provide effective vaccines and diagnostic tools for Brucellosis. Its strength lies in its established relationships with veterinary professionals and livestock producers, allowing for seamless product integration into existing animal health management practices. Furthermore, Elanco's active engagement in educational initiatives contributes to improved awareness and understanding of Brucellosis, thereby strengthening its market presence. The ability to offer comprehensive support and service provisions to livestock producers sets Elanco apart from its competitors, establishing it as a leader in the UK market. Intervet, a key player in the UK Brucellosis Market, is known for its robust portfolio of veterinary vaccines and pharmaceutical products tailored specifically for the prevention and treatment of Brucellosis in livestock. With a strong focus on innovation, Intervet continuously invests in research and development to enhance its offerings, ensuring they meet the evolving needs of the agriculture sector. Their extensive market presence is supported by a strategic approach that includes partnerships with veterinary practices and agricultural organizations, reinforcing their commitment to animal health and biosecurity measures. Intervet's strength lies in its ability to create tailored solutions that address the specific challenges faced by farmers in the UK. This is further underscored by their active engagement in collaborations and potential mergers that expand their reach and enhance their competitive edge within the Brucellosis Market. The company's comprehensive offerings enable them to cater to a wide range of livestock health needs, positioning them as a vital contributor to the ongoing combat against Brucellosis in the UK. **Key Companies in the UK Brucellosis Market Include** - Elanco - Intervet - Hipra - Neogen - MSD Animal Health - Vetoquinol - Heska - Merck Animal Health - Boehringer Ingelheim - Ceva Santé Animale - Virbac - Bimeda - Wockhardt - Lohmann Animal Health - Zoetis **UK Brucellosis****Market****Developments** The UK Brucellosis Market has seen several notable developments recently, particularly in the ongoing efforts to control the disease among livestock, enhancing the demand for effective diagnostics and vaccines. Companies such as Elanco and Merck Animal Health have been actively involved in Research and Development initiatives aimed at improving their product offerings for Brucellosis management. Furthermore, market growth has been observed, attributed to increased awareness and regulations concerning animal health; the market is projected to grow significantly in the coming years, contributing to the economic stability of the livestock sector. Notably, in October 2022, Intervet announced the acquisition of key assets from a smaller competitor, strengthening its position in the Brucellosis vaccine segment. Additionally, Boehringer Ingelheim has expanded its facility in the UK devoted to producing vaccines, underscoring a commitment to addressing livestock disease challenges. The UK government has also allocated funds for disease management, incentivizing innovation and research to combat Brucellosis effectively. Overall, the convergence of regulatory support, company expansions, and technological advancements is shaping a dynamic landscape in the UK Brucellosis Market. **UK Brucellosis Market Segmentation Insights** **Brucellosis Market species Outlook** - Brucella suis - B. abortus - B. melitensis ## Market Drivers ### Rising Incidence of Brucellosis Cases The increasing incidence of brucellosis cases in the UK is a critical driver for the brucellosis market. Reports indicate that the number of reported cases has risen by approximately 15% over the past five years, prompting heightened awareness among healthcare professionals and the public. This trend necessitates improved diagnostic and treatment options, thereby stimulating demand within the market. The UK government has initiated various public health campaigns aimed at educating farmers and veterinarians about the disease, which further emphasizes the need for effective solutions. As the incidence continues to rise, the brucellosis market is likely to experience growth, driven by the urgent need for innovative products and services to combat this zoonotic disease. ### Growing Awareness of Zoonotic Diseases The growing awareness of zoonotic diseases among the UK population is influencing the brucellosis market. Public health campaigns and educational initiatives have highlighted the risks associated with zoonotic infections, including brucellosis. This heightened awareness is likely to lead to increased demand for preventive measures, such as vaccinations and diagnostic tests. In 2025, surveys indicate that approximately 60% of the population is now aware of brucellosis and its transmission routes, compared to just 30% five years ago. This shift in public perception is expected to drive market growth as individuals and healthcare providers seek effective solutions to mitigate the risks associated with zoonotic diseases. ### Strengthening of Regulatory Frameworks The strengthening of regulatory frameworks surrounding animal health and food safety is a vital driver for the brucellosis market. The UK government has implemented stricter regulations to ensure the control and prevention of brucellosis in livestock. These regulations are designed to enhance surveillance, reporting, and management of the disease, thereby creating a more robust environment for market growth. In 2025, compliance with these regulations is expected to increase, leading to greater demand for diagnostic tools and vaccines. As the regulatory landscape evolves, market participants will need to adapt to these changes, which may present both challenges and opportunities for innovation within the brucellosis market. ### Increased Investment in Veterinary Health Investment in veterinary health is a significant driver for the brucellosis market. The UK government and private sector stakeholders are allocating substantial funds to enhance animal health services, which includes the prevention and control of brucellosis. In 2025, it is estimated that veterinary health expenditure will reach £1.2 billion, with a notable portion directed towards brucellosis-related initiatives. This financial commitment is expected to foster advancements in vaccination programs and diagnostic tools, ultimately benefiting the brucellosis market. Furthermore, as livestock health becomes a priority, the demand for effective brucellosis management solutions is anticipated to rise, creating opportunities for market players to innovate and expand their offerings. ### Technological Advancements in Treatment Options Technological advancements in treatment options are poised to significantly impact the brucellosis market. Innovations in pharmaceuticals and biotechnology are leading to the development of more effective treatments for brucellosis, which is crucial given the disease's complex nature. In 2025, the introduction of new antibiotic therapies and improved vaccine formulations is anticipated to enhance treatment outcomes for affected individuals and livestock. These advancements not only improve patient care but also contribute to the overall growth of the brucellosis market. As healthcare providers adopt these new technologies, the market is likely to expand, driven by the demand for cutting-edge solutions that address the challenges posed by brucellosis. ## Future Outlook The [Brucellosis Market](https://www.marketresearchfuture.com/reports/brucellosis-market-5159) is projected to grow at a 7.02% CAGR from 2025 to 2035, driven by increased awareness, advancements in diagnostics, and rising livestock health concerns. **New opportunities:** - Development of rapid diagnostic kits for brucellosis detection - Expansion of telemedicine services for remote consultations - Investment in vaccine research for livestock to enhance herd immunity By 2035, the market is expected to achieve robust growth, driven by innovative solutions and heightened health awareness. ## Segment Insights ### By Species: Brucella melitensis (Largest) vs. Brucella canis (Fastest-Growing) The market share distribution among the species segment reveals that Brucella melitensis holds the largest share due to its prevalence in livestock and significant public health implications. Following this, Brucella abortus and Brucella suis are also notable contributors, but their shares are smaller compared to Brucella melitensis. Brucella canis, although having a smaller market share currently, is rapidly gaining attention due to increased awareness of zoonotic diseases that affect both animals and humans. Growth trends within this segment indicate a rise in diagnostic initiatives focusing on Brucella species, particularly Brucella canis, as pet ownership increases and awareness of animal diseases grows. Regulatory measures and health policies aimed at controlling brucellosis are driving research and development efforts, which could further enhance the visibility of emerging species in the market. As healthcare professionals emphasize prevention and control, the overall market dynamics are expected to evolve, creating opportunities for both established and emerging segments. Brucella melitensis (Dominant) vs. Brucella canis (Emerging) Brucella melitensis remains the dominant species in the UK brucellosis market, primarily influencing the epidemiological landscape due to its association with goats and sheep. The focus on controlling this species stems from its significant impact on livestock productivity and human health risks. Conversely, Brucella canis stands out as an emerging player, fueled by the rising incidence of brucellosis in dogs and its zoonotic potential. This species is increasingly recognized in veterinary medicine, with expanded efforts in diagnostics and treatment protocols. As pet ownership grows, understanding and managing Brucella canis will likely become crucial, making it an essential area for further research and market investment. ### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing) The diagnosis segment of the UK brucellosis market showcases a diverse array of testing methodologies. Serological tests currently hold the largest market share, driven by their widespread adoption owing to their cost-effectiveness and reliability. In contrast, molecular techniques are emerging as the fastest-growing segment, reflecting an increasing preference for rapid and accurate diagnostic solutions that can aid in timely patient management. Growth in the diagnosis segment is being propelled by technological advancements and greater awareness regarding brucellosis. The rising incidence of brucellosis in livestock and consequently in humans is prompting healthcare providers to seek improved diagnostic methods. Furthermore, the integration of advanced imaging techniques such as X-rays and MRIs also contributes to the evolving dynamics of this segment, as practitioners aim for comprehensive diagnostic approaches. Serological Tests (Dominant) vs. Molecular Techniques (Emerging) Serological tests have established a dominant position in the UK brucellosis market due to their extensive use in initial screening. These tests are typically regarded as reliable indicators to detect antibodies, making them a frontline approach for clinicians. Meanwhile, molecular techniques represent an emerging trend, leveraging innovations in genetic analysis to provide precise and swift results. As healthcare systems continue to evolve and emphasize speed, molecular testing methods are quickly becoming integral in clinical settings. Their ability to detect the pathogen's genetic material leads to quicker diagnosis and improved patient outcomes. The coexistence of these methodologies signifies a balanced approach within the diagnostic landscape, catering to diverse clinical needs. ### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing) In the UK brucellosis market, the treatment segment is primarily characterized by three key components: antibiotics, vaccines, and others. Antibiotics hold the largest market share due to their established efficacy in treating brucellosis in livestock and humans. Vaccines, while traditionally considered supportive, are rapidly gaining traction as awareness grows regarding prevention strategies, turning them into a competitive segment. Others comprise various alternative treatments that appeal to niche markets but currently represent a smaller portion of the overall segment. The growth trends in this segment highlight a significant shift towards preventative measures, particularly vaccines, which are becoming increasingly recognized for their role in disease management. As research continues to support the efficacy of these vaccines, their adoption is expected to surge, capitalizing on the focus on public health and biosecurity. Conversely, antibiotics, although dominant, face challenges due to rising antimicrobial resistance, urging a need for innovative solutions and promising alternative therapies. Antibiotics (Dominant) vs. Vaccines (Emerging) Antibiotics are the dominant force in the treatment segment, primarily utilized for their effectiveness in clinical settings. Their extensive application in treating active brucellosis cases in both animal and human populations drives a substantial share of the market. However, with increasing concerns regarding antimicrobial resistance, the focus is gradually shifting towards preventive healthcare solutions. Vaccines represent an emerging category that is rapidly developing, characterized by cutting-edge research and improvements in technology to enhance their efficacy and safety. As more farmers and healthcare professionals recognize the importance of vaccination in controlling the spread of brucellosis, the vaccine segment is witnessing a remarkable upward trajectory, supported by governmental initiatives and public awareness campaigns. ### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Pharmaceutical & Biotechnology Companies (Fastest-Growing) In the UK brucellosis market, the end-user segment is primarily dominated by hospitals and diagnostic centers, holding a significant share due to their essential role in disease diagnosis and treatment. These facilities leverage advanced diagnostic tools, thereby ensuring that cases of brucellosis are promptly identified and treated. In contrast, pharmaceutical and biotechnology companies occupy an emerging position, focusing on the development of novel therapies and diagnostics specific to brucellosis, thereby contributing to their rapid market growth. The growth trends in this segment are influenced by several factors. Increased research initiatives in universities and academic institutions enhance the demand for innovative solutions related to brucellosis. Additionally, rising incidences of zoonotic diseases like brucellosis highlight the critical need for effective treatments and diagnostics, pushing hospitals, diagnostic centers, and pharmaceutical companies to expand their offerings in this sector. Furthermore, collaborations between academic institutes and biotech firms are fueling advancements in research and technology specific to brucellosis. Hospitals & Diagnostic Centers (Dominant) vs. Pharmaceutical & Biotechnology Companies (Emerging) Hospitals and diagnostic centers are the dominant players in the UK brucellosis market. They are equipped with sophisticated laboratory facilities and skilled personnel to conduct timely and accurate testing for brucellosis. This segment's prominence stems from its direct impact on patient care and public health management, enhancing the overall healthcare response to infectious diseases. On the other hand, pharmaceutical and biotechnology companies are emerging as critical players in the market, focusing on developing new treatment options and diagnostic tests. These companies are at the forefront of innovation, utilizing cutting-edge research to address unmet medical needs in brucellosis management. The synergy between these two segments fosters a dynamic ecosystem aimed at improving health outcomes related to brucellosis. ## Competitive Benchmarking The brucellosis market exhibits a competitive landscape characterized by a blend of established players and emerging innovators. Key growth drivers include increasing awareness of zoonotic diseases, advancements in diagnostic technologies, and a rising demand for effective vaccines. Major companies such as Zoetis Inc (US), Merck & Co Inc (US), and Boehringer Ingelheim (DE) are strategically positioned to leverage these trends. Zoetis Inc (US) focuses on innovation in vaccine development, while Merck & Co Inc (US) emphasizes partnerships to enhance its product portfolio. Boehringer Ingelheim (DE) is actively pursuing regional expansion, particularly in areas with high brucellosis prevalence, thereby shaping a competitive environment that prioritizes both innovation and accessibility.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The market structure appears moderately fragmented, with a mix of large multinational corporations and smaller specialized firms. This fragmentation allows for diverse strategies, yet the collective influence of key players like Ceva Santé Animale (FR) and Virbac (FR) is significant, as they contribute to a competitive dynamic that fosters innovation and responsiveness to market needs. In October Zoetis Inc (US) announced a collaboration with a leading veterinary university to develop a next-generation brucellosis vaccine. This strategic move underscores the company's commitment to innovation and positions it to capture a larger market share by addressing unmet needs in vaccine efficacy. The collaboration is likely to enhance Zoetis's reputation as a leader in veterinary health solutions, potentially leading to increased sales and market penetration. In September Merck & Co Inc (US) launched a new diagnostic tool aimed at early detection of brucellosis in livestock. This tool is expected to streamline testing processes for farmers, thereby reducing the economic impact of the disease. The introduction of this diagnostic innovation reflects Merck's strategy to integrate advanced technology into its offerings, which may strengthen its competitive edge in the market. In August Boehringer Ingelheim (DE) expanded its distribution network in Eastern Europe, targeting regions with high incidences of brucellosis. This expansion is indicative of the company's strategy to enhance accessibility to its products, thereby addressing a critical gap in the market. By increasing its presence in these areas, Boehringer Ingelheim is likely to improve its market share and contribute to overall public health efforts in combating brucellosis. As of November current competitive trends in the brucellosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostics and treatment. Strategic alliances among key players are shaping the landscape, fostering innovation and collaboration. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident. Companies that prioritize these aspects are likely to differentiate themselves in a market that demands both efficacy and efficiency. ## Recent News & Developments The UK Brucellosis Market has seen several notable developments recently, particularly in the ongoing efforts to control the disease among livestock, enhancing the demand for effective diagnostics and vaccines. Companies such as Elanco and Merck Animal Health have been actively involved in Research and Development initiatives aimed at improving their product offerings for Brucellosis management. Furthermore, market growth has been observed, attributed to increased awareness and regulations concerning animal health; the market is projected to grow significantly in the coming years, contributing to the economic stability of the livestock sector. Notably, in October 2022, Intervet announced the acquisition of key assets from a smaller competitor, strengthening its position in the Brucellosis vaccine segment. Additionally, Boehringer Ingelheim has expanded its facility in the UK devoted to producing vaccines, underscoring a commitment to addressing livestock disease challenges. The UK government has also allocated funds for disease management, incentivizing innovation and research to combat Brucellosis effectively. Overall, the convergence of regulatory support, company expansions, and technological advancements is shaping a dynamic landscape in the UK Brucellosis Market. ## Report Scope | MARKET SIZE 2024 | 24.66(USD Million) | | --- | --- | | MARKET SIZE 2025 | 26.39(USD Million) | | MARKET SIZE 2035 | 52.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.02% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Zoetis Inc (US), Merck & Co Inc (US), Boehringer Ingelheim (DE), Ceva Santé Animale (FR), Virbac (FR), Heska Corporation (US), Vetoquinol (FR), Phibro Animal Health Corporation (US) | | Segments Covered | Species, Diagnosis, Treatment, End-User | | Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the brucellosis market. | | Key Market Dynamics | Rising regulatory scrutiny and advancements in diagnostic technologies are reshaping the brucellosis market landscape. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the overall market valuation of the UK brucellosis market in 2024?** A: The overall market valuation was $24.66 Million in 2024. **Q: What is the projected market valuation for the UK brucellosis market by 2035?** A: The projected valuation for 2035 is $52.0 Million. **Q: What is the expected CAGR for the UK brucellosis market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 7.02%. **Q: Which companies are considered key players in the UK brucellosis market?** A: Key players include Zoetis Inc, Merck & Co Inc, Boehringer Ingelheim, Ceva Santé Animale, and others. **Q: What are the main segments of the UK brucellosis market?** A: The main segments include Species, Diagnosis, Treatment, and End-User. **Q: What was the market value for Brucella melitensis in 2024?** A: The market value for Brucella melitensis was $7.0 Million in 2024. **Q: How much is the market for antibiotics projected to grow by 2035?** A: The market for antibiotics is projected to grow to $17.0 Million by 2035. **Q: What is the expected market value for serological tests in 2025?** A: The expected market value for serological tests is projected to be $7.0 Million in 2025. **Q: What is the projected market value for hospitals & diagnostic centers by 2035?** A: The projected market value for hospitals & diagnostic centers is $17.0 Million by 2035. **Q: What was the market value for vaccines in 2024?** A: The market value for vaccines was $10.0 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-brucellosis-market-53588*